Stock events for Armata Pharmaceuticals, Inc. (ARMP)
Armata Pharmaceuticals announced its fourth-quarter and full-year 2025 financial results, with a delay in the announcement. The company received FDA Qualified Infectious Disease Product (QIDP) designation for AP-SA02. In November, Armata Pharmaceuticals announced a Key Opinion Leader Webinar on S. aureus Bacteremia and AP-SA02. As of April 10, 2026, the stock price of Armata Pharmaceuticals was $11.12, with a market capitalization of $407 million. Over the past year, ARMP's stock performance exceeded both the US Biotechs industry and the broader US Market.
Demand Seasonality affecting Armata Pharmaceuticals, Inc.’s stock price
The provided search results do not contain specific information about demand seasonality for Armata Pharmaceuticals, Inc.'s products and services. Demand is likely driven by medical need and regulatory approvals rather than seasonal patterns.
Overview of Armata Pharmaceuticals, Inc.’s business
Armata Pharmaceuticals, Inc. is a clinical-stage biotechnology company focused on developing pathogen-specific bacteriophage therapeutics to combat antibiotic-resistant bacterial infections. The company operates in the Healthcare sector and Biotechnology industry, utilizing a proprietary bacteriophage-based technology platform. Its major product candidates include AP-SA02 for complicated Staphylococcus aureus bacteremia, AP-PA02 for chronic pulmonary infections caused by Pseudomonas aeruginosa, and AP-PA03 for the treatment of pneumonia. Armata is headquartered in Los Angeles, California, and operates a 56,000 square foot facility for phage product development, including in-house cGMP drug manufacturing suites. The company has completed three Phase 2 clinical trials to date.
ARMP’s Geographic footprint
Armata Pharmaceuticals, Inc. is based in Los Angeles, California, United States. Its primary operations and manufacturing facility are located there, and it targets a potential worldwide market. The company's stock is listed on the NYSE American exchange and traded on various European stock exchanges.
ARMP Corporate Image Assessment
The provided search results do not contain specific information about Armata Pharmaceuticals, Inc.'s brand reputation in the past year or any events that have specifically affected it.
Ownership
The provided search results do not contain specific details about major institutional and individual owners of Armata Pharmaceuticals, Inc.
Ask Our Expert AI Analyst
Price Chart
$8.89
